Gordon Ringold, PhD, CEO

Gordon is a biotechnology entrepreneur. Quadriga is an oncology start-up focused on developing targeted anti-cancer drugs. He is currently on the board of directors for Maverix Biomics, a bio-informatics company co-founded by Prof Todd Lowe (UCSC) and is on the board of directors of Ardelyx, Alexza, and 3V Biopharma..  From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and Alavita. From 1991 to 2000, Gordon was CEO and Scientific Director of Affymax Research Institute (acquired by Glaxo in 1995) where he managed the development of novel technologies to accelerate the pace of drug discovery; prior to that he was VP and Director of the Institute for Cancer and Developmental Biology at Syntex Corporation (1986-1991). Gordon received his Ph.D. in the laboratory of Dr. Harold Varmus, before joining the Stanford University School of Medicine, Department of Pharmacology (1978-1987). While on the Stanford faculty he invented technologies for manufacturing of recombinant proteins in mammalian cells, now widely used for production of dozens of therapeutic products and received the John J. Abel Award as the best Pharmacologist in the US under the age of 35. Gordon is an alumnus of Crown College, UC Santa Cruz, 1972.

Peter Y. Tam, MBA, President & COO

Peter is a pharmaceutical executive with over 25 years of drug development experience. He is currently President and COO of Quadriga Biosciences. Prior to joining Quadriga, Peter served as President and a member of the Board of Directors of VIVUS Inc, a biopharmaceutical company that develops therapies for the treatment of obesity, diabetes, and urology. Under his leadership, VIVUS obtained four consecutive drug approvals from product inception.  Peter built the company’s R&D pipeline through licensing and acquisition. He built and led R&D teams (regulatory, clinical and CMC), created and developed patent portfolio and collaborated with FDA, corporate partners and stakeholders to ensure regulatory approvals for company's pipeline products. He also helped raise over $500M in corporate financing during his 20-year tenure at VIVUS (1993-2012). He has extensive management experience in drug development , corporate/business development, senior executive leadership and board experience in the biopharmaceutical industry.  Prior to VIVUS, Peter also held various research and clinical development positions at Genentech and XOMA Corporation.

Peter holds a B.S. in Chemistry from University of California Berkeley and an MBA from Santa Clara University. He has a number of patents approved and pending to his name.

Ron Weitzman, MD, Chief Medical Officer (Consulting)

Ron is a US trained board certified medical oncologist having worked in the biopharmaceutical industry since 1999. Over his career, Ron has worked in all areas of clinical development including phase 1, 2 and 3 clinical trials. He has drug development experience in both solid and hematological malignancies and has interacted extensively with FDA, EMEA, Canadian and Japanese health authorities. In his most recent role at Exelixis, he oversaw cabozantinib's (XL184) development in prostate cancer with two ongoing phase 3 registrational studies underway. Over the years, Ron has managed both large and small groups and very much enjoys mentoring colleagues.

S. Stuart Hwang, PhD, CBO

Stuart has 10 years in pharmaceutical business development with a cumulative transaction value in excess of $1B. He has led corporate development efforts to establish strategic alliances, in/out licensing, and M&A. Earlier, he was a corporate development and licensing consultant for biotech companies, led business development at Astex (ASTX; acquired by Otsuka) partnerships (GSK R&D collab.), licensing, and M&A (Astex Tx). Prior to that he held leadership roles in business development and commercialization at Perlegen and Agilent.

He has 20 years experience leading drug and diagnostic R&D teams at SuperGen, Cor Therapeutics, Millennium, Celera, Agilent, and at UCSF/LBNL driving 6 INDs and supported the development of 3 marketed drugs. He developed deep sequencing and genome partitioning algorithms at Celera Genomics and at Agilent, several first whole genome arrays (rat, stem cells, & important agricultural genomes). He also discovered a breast cancer gene that is part of a widely used breast cancer panel for early diagnosis.

Stuart is an inventor on several patents, authored 20 journal articles, and presented numerous papers at global scientific & business meetings. He received a BA in Biology with High Honors, UCSC, and PhD in Endocrinology at UC Berkeley, Cancer Research Lab under a NCI fellowship & post-doctoral work at UCSF & the Lawrence Berkeley National Laboratory as a Distinguished Human Genome Postdoctoral Fellow (DOE).